Mark Elliott Boulding Sells 4,879 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 4,879 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $77.44, for a total transaction of $377,829.76. Following the completion of the sale, the vice president owned 117,659 shares in the company, valued at $9,111,512.96. The trade was a 3.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $133,816.05.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.55, for a total transaction of $171,196.30.
• On Monday, November 17th, Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.99, for a total transaction of $213,683.88.

PTC Therapeutics Stock Down 0.5%

PTCT traded down $0.39 during trading on Thursday, reaching $76.85. The stock had a trading volume of 1,625,361 shares, compared to its average volume of 1,684,365. The stock has a 50 day moving average of $76.26 and a two-hundred day moving average of $62.43. The firm has a market capitalization of $6.17 billion, a price-to-earnings ratio of 8.98 and a beta of 0.49. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($1.19) by $1.39. The company had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter last year, the firm posted ($1.39) EPS. On average, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
• Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
• Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
• Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

Wall Street Analyst Weigh In

PTCT has been the topic of several recent analyst reports. Royal Bank Of Canada lowered PTC Therapeutics from an “outperform” rating to a “sector perform” rating and upped their price target for the company from $82.00 to $91.00 in a research report on Monday, December 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Morgan Stanley reissued an “overweight” rating and issued a $90.00 price target on shares of PTC Therapeutics in a research report on Thursday. Wells Fargo & Company boosted their price objective on shares of PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Finally, Barclays upped their price objective on shares of PTC Therapeutics from $46.00 to $68.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $77.27.

Institutional Trading of PTC Therapeutics

Several large investors have recently modified their holdings of the company. Empowered Funds LLC acquired a new position in shares of PTC Therapeutics during the first quarter worth approximately $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in PTC Therapeutics by 11.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock worth $9,109,000 after acquiring an additional 18,504 shares during the period. Bayforest Capital Ltd bought a new position in PTC Therapeutics during the first quarter worth $415,000. Intech Investment Management LLC raised its stake in PTC Therapeutics by 62.8% during the 1st quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock valued at $2,003,000 after purchasing an additional 15,167 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in PTC Therapeutics by 6.1% in the 1st quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock valued at $1,904,000 after purchasing an additional 2,140 shares during the period.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.